The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Anthropic is reportedly targeting an IPO in September or early October 2026, according to the Wall Street Journal. In investor meetings, it said it plans to expand healthcare and biology AI use cases. The article highlights potential AI-biotech beneficiaries, citing results and guidance for Absci, Recursion, Schrodinger, Twist Bioscience, and Tempus AI, including Tempus Q2 revenue of $382.49M and raised FY guidance to $1.595 to $1.605B.
How this was made
The 30-second read
Why it matters
It argues that AI-adjacent healthcare could rally ahead of the IPO and lists five AI-native biotech/synthetic biology stocks with recent financial metrics and catalysts.
Market read
Traders are offered a thematic watchlist for AI-healthcare rotation, anchored to an expected Anthropic IPO window, but the text is not a single breaking catalyst for any one stock.
What to watch
Execution risk remains high for AI-biotech models, and guidance raises or quarterly beats can already be partially priced given the large year-to-date moves cited for some names.
Background
The article claims Anthropic is targeting a large 2026 IPO in September or early October and says it is pitching healthcare and biology AI use cases.
Ticker impact
Absci is highlighted for multiple 2026 readouts and a “data-rich year” CEO quote, with cash runway into 1H 2028.
Near-term sympathy bid possible if AI-healthcare rotation accelerates, but no single fresh catalyst is disclosed here.
The piece cites prior financial figures and analyst targets, plus CEO commentary, without a new filing, trial result, or deal announcement.
Recursion is cited for Q2 revenue decline, narrowed net loss, and lowered 2026 cash opex guidance by $15 million to $375 million.
Potential stabilization or modest upside bias if investors focus on loss narrowing and funding into early 2028.
The article provides specific, decision-relevant guidance and cash/opex numbers, even if it is not framed as a brand-new filing.
Schrodinger is described with Q1 revenue beat, drug discovery revenue doubling, and Bunsen agentic AI co-scientist launches this summer.
Could attract momentum flows if traders treat the agentic AI launch and revenue strength as near-term catalysts.
The article includes specific quarterly results and launch timing, but also references an Eli Lilly-Ajax deal valuation that may not be newly disclosed.
Twist Bioscience is cited for Q3 revenue growth, gross margin expansion to 52.8%, and raised full-year guidance to $456 to $457 million.
Higher probability of continued upside bias versus peers if the market rewards guidance raises and margin expansion.
Raised full-year guidance and margin expansion are concrete datapoints that can directly affect valuation expectations.
Tempus AI is described with Q2 revenue growth, a fifth consecutive EPS beat, raised full-year guidance to $1.595 to $1.605 billion, and a pending $1.5 billion Personalis acquisition.
Likely to outperform on AI-healthcare rotation and acquisition-related optimism, subject to deal execution risk.
The article provides multiple specific financial and deal details, but it is still framed as a “targeted IPO” thematic trade rather than a single fresh breaking disclosure.
Market effects
Reinforces capital rotation toward AI-native biotech and synthetic biology as a proxy for an Anthropic healthcare-biased IPO narrative.
Primarily US-listed small and mid-cap biotech/AI names, with potential spillover into broader healthcare growth sentiment.
Could influence global AI-healthcare funding appetite, but the article’s concrete catalysts are company-specific and US-focused.
Counterpoint
The “Anthropic IPO” framing may be more narrative than catalyst; without a confirmed deal date or new filings for these names, the trade could fade quickly.
Key entities
- companyAnthropic
Reportedly targeting a public debut in September or early October, with a pitch extending beyond chatbots into healthcare and biology AI.
- companyTempus AI
Cited for Q2 revenue growth, a fifth consecutive EPS beat, raised full-year guidance, and a pending $1.5 billion Personalis acquisition.
- companyTwist Bioscience
Cited for Q3 revenue growth, gross margin expansion, and raised full-year guidance to $456 to $457 million.
